Зофеноприл – выбор поликлинического врача при лечении артериальной гипертензии

1. Европейские рекомендации по лечению больных со стабильной стенокардией. EHJ 2006.
2. Комитет экспертов ВОЗ. Борьба с артериальной гипертензией. Серия технических докладов ВОЗ, 1999; с. 862.
3. Mancia G, De Backer G, Dominiczak A et al. Management of Arterial Hypertension of the European Society of Hypertension. Eur Soc Cardiology 2007.
4. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) & of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87.
5. Subissi A, Evangelista S, Giachetti A. Preclinical profile of zofenopril: an angiotensin converting enzyme inhibitor with peculiar cardioprotective properties. Cardiovasc Drug Rev 1999; 17: 115–33.
6. Malacco E, Giusti A on behalf of the Zofenopril Study Group. Once-daily zofenopril provides 24-hour ambulatory blood pressures control in hypertensive patients aged under 65 years. Am J Hypertension 1998; 11 (4 Part. 2): 70.
7. Napoli C, Sica V, De Nigris E et al. Sulphydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: e5.
8. Desideri G, Grassi D, Croce G et al. Different Effects of Angiotensin Converting Enzyme Inhibitors on Endothelin-1 and Nitric Oxide Balance in Human Vascular Endothelial Cells: Evidence of an Oxidant-Sensitive Pathway. Mediators Inflamm 2008; 305087.
9. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells; Biochem Pharmacol 1990; 40 (9): 2169–75.
10. Ambrosioni E, Borghi C, Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med 1995; 332 (2): 80–5.
11. Borghi C, Bacchelli S, Esposti DD et al. Effects of the administrationof an angiotensin-converting enzyme inhibitor during the acutephase of myocardial infarction in patients with arterial hypertension. SMILE Study Investigators. Survival of Myocardial Infarction Long-term Evaluation. Am J Hypertens 1999; 12: 665–72.
12. Borghi C, Bacchelli S, Esposti DD et al. SMILE Study. Effects of theearly ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care 2003; 26: 1862–8.
13. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation-2 Working PartyDouble-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J 2003; 1 (45): 80–7.
14. Claudio Borghi, MD, and Ettore Ambrosioni, MD, on behalf of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Group Bologna, Italy. Am Heart J 2007; 153: 445. e7244. e14.
15. Mallion JM et al. An evaluation of the initial and long-term antihypertensive efficacy of zofenopril compared with enalapril in mild to moderate hypertension. Blood Press 2007; 16 (Suppl. 2): 13–8.
16. Malacco E et al. Zofenopril Versus Lisinopril in the Treatment of Essential Hypertension in Elderly Patients. Clin Drug Invest 2005; 25 (3): 175–82.
17. Leonetti G et al. A similar 24-h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients. Blood Press 2006; 15 (Suppl. 1): 18–26.
18. Narkiewicz K. Comparison of home and office blood pressure in hypertensive patients treated with zofenopril or losartan Blood Pressure 2007; 16 (Suppl. 2): 7–12.
19. Sargent CA, Sleph PG, Dzwonczyk S et al. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel. J Pharmacol Exp Ther 1993; 265: 609–18.
20. Zusman RM. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acidprostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis 1987; 10 (Suppl. 1): 13–23.
21. Brogelli L, Parenti A, Capaccioli S et al. The angiotensin con-verting enzyme inhibitor zofenoprilat prevents endothelial cell apoptosis and promotes coronary angiogenesis «in vitro» [abstract]. FASEB J 1999; 13: A528.
22. Chopra M, McMurray J, Stewart J et al. Free radical scavenging: a potentially beneficial action of thiol-containing angiotensin converting enzyme inhibitors. Biochem Soc Trans 1990; 18 (6): 1184–5.
23. Evangelista S, Manzini S. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res 2005; 33 (1): 42–54.
24. Scribner AW, Loscalzo J, Napoli C. The effect of angiotensin-converting enzyme inhibition on endothelial function and oxidant stress. Eur J Pharmacol 2003; 482 (1–3): 95–9.
25. Плисюк А.Г., Арзамасцева Н.Е., Кулев Б.Д. и др. Влияние ингибиторов АПФ зофеноприла и периндоприла на показания окислительного стресса и эндотелиальную функцию у больных со стабильной ишемической болезнью сердца и артериальной гипертонией. Практикующий врач. 2008; 6: 14–6.
26. Borghi C, Ambrosioni E. Survival of Myocardial Infarction Long-term Evaluation Study Group. Effects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE) – ISCHEMIA study. Am Heart J 2007; 153 (3): 445 .e7–14.
27. Halpern MT, Vincze G, Stewart WF, Khan ZM. Compliance with hypertension therapy and long-term cardiovascular outcomes. J Hypertens 2006; 24 (Suppl. 4): S154.
28. Halpern MT, Vincze G, Stewart WF et al. Persistence with hypertension therapy and long-term cardiovascular outcomes. J Hypertens 2006; 24 (Suppl. 4): S182.
29. Malacco E, Gastiglioni G, Corradi L et al. Dose-response relationship of zofenopril in essential hypertension. Clin Drug Invest 2002; 22 (1): 9–15.
30. Cыркин А.Л., Добровольский А.В. Трудности, возникающие при лечении ингибиторами АПФ больных сердечно-сосудистыми заболеваниями. Кардиология и сосудистая хирургия. 2008; 1.
31. Omboni S, Borghi C. Zofenopril and incidence of cough: a review of published and unpublished data. Ther Clin Risk Manag 2011; 7: 459–71.
32. Singhvi SM, Foley JE, Willard DA et al. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79.
33. Marzo A, Dal Bo L, Mazzucchelli P et al. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung 1999; 49 (12): 992–6.
34. Zannad F et al. Am J Hypertens 1996; 9 (7): 663–4.
35. Singhvi SM, Foley JE, Willard DA, Morrison RA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci 1990; 79 (11): 970–3.
36. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. JАСС 1992; 20 (7): 1549–55.
37. FitzGerald GA, Oates JA, Hawiger J et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676–88.
38. Al-Khadra A, Salem D, Rand W. Antiplatelet agents and survival: a cohort analysis from the studies of left ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998; 31: 419–25.
39. Harjai KJ, Nunez E, Turgut T, Newman J. Effect of combined aspirin and angiotensin-converting enzyme inhibitor therapy versus angiotensin-converting enzyme inhibitor therapy alone on readmission rates in heart failure. Am J Cardiol 2001; 87 (4): 483–7.
40. Арутюнов Г.П., Розанов А.В. Некоторые аспекты совместного применения ацетилсалициловой кислоты и ингибиторов АПФ у больных в постинфарктном периоде. Клин. фармакология и терапия. 2000; 9 (4): 16–8.
41. Leor J, Reicher-Reiss H, Goldbourt U et al. Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. A cohort study of 11 575 patients with coronary artery disease. J Am Coll Cardiol 1999; 33: 1920–5.
42. Борджи К., Амбросиони Е., Ново С. и др. от имени Рабочей группы исследования SMILE-4. Сравнение терапии зофеноприлом и рамиприлом в сочетании с ацетилсалициловой кислотой у пациентов с систолической дисфункцией левого желудочка после острого инфаркта миокарда: результаты европейского многоцентрового рандомизированного двойного слепого исследования в параллельных группах (SMILE-4). Рос. кардиол. журн. 2012; 96 (4): 5–13. 
43. Blood Pressure Lowering treatment trialists Collaboration. Effects of ACE inhibitors, calcium antagonists & other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 1995; 64; 2000; 356.

Я.А.Орлова

Медицинский научно-образовательный центр ФГОУ ВПО МГУ им. М.В.Ломоносова